Loading...
Loading...
KMDA| Name | Value |
|---|---|
| Revenues | 44.0M |
| Cost of Revenue | 23.3M |
| Gross Profit | 20.7M |
| Operating Expense | 13.0M |
| Operating I/L | 7.8M |
| Other Income/Expense | -1.2M |
| Interest Income | 0.5M |
| Pretax | 6.6M |
| Income Tax Expense | 2.6M |
| Net Income/Loss | 4.0M |
Kamada Ltd. is a biopharmaceutical company that specializes in providing plasma-derived protein therapeutics. The company operates in two segments, Proprietary Products and Distribution, offering a wide range of products for various medical conditions such as rabies, cytomegalovirus disease, immune thrombocytopenic purpura, hepatitis B, varicella, AATD, hemolytic disease of newborns, asthma, allergic rhinitis, immunodeficiency-related conditions, hemophilia, Japanese encephalitis, Salmonella Typhi, nephropathic cystinosis, alpha-mannosidosis, and prostate cancer. Kamada markets its products through strategic partners in the United States and international distributors, generating revenue from the sale of its therapeutic products.
